J 2010

Post prostatectomy in-vitro biopsy findings in patients with a clinically significant cancer: How reliable are the results of Vienna nomogram biopsy?

MAREČKOVÁ, Natália, Dalibor PACÍK, Aleš ČERMÁK, Leoš KŘEN, Zdeněk PAVLOVSKÝ et. al.

Basic information

Original name

Post prostatectomy in-vitro biopsy findings in patients with a clinically significant cancer: How reliable are the results of Vienna nomogram biopsy?

Authors

MAREČKOVÁ, Natália (703 Slovakia, guarantor, belonging to the institution), Dalibor PACÍK (203 Czech Republic, belonging to the institution), Aleš ČERMÁK (203 Czech Republic, belonging to the institution), Leoš KŘEN (203 Czech Republic, belonging to the institution) and Zdeněk PAVLOVSKÝ (203 Czech Republic, belonging to the institution)

Edition

European Urology Suplements, Elsevier B.V. 2010, 1569-9056

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.139

RIV identification code

RIV/00216224:14110/10:00046908

Organization unit

Faculty of Medicine

UT WoS

000281880100467

Keywords (in Czech)

karcinom prostaty in-vitro biopsie Vídeňský nomogram

Keywords in English

prostate cancer in-vitro biopsy Vienna nomogram
Změněno: 18/1/2011 17:35, MUDr. Vítězslav Vít

Abstract

ORIG CZ

V originále

The precisely performed in-vitro biopsy following the Vienna nomogram suggested a clinically significant cancer in only 40.43% of patients with the clinically sign ificant disease proved in final RAPE specimen.This findings should warn us of a real chance of underestimation of potentially clinically significant cancer

In Czech

Správně provedená in vitro biopsie podle Vídeňského nomogramu ukazuje klinicky signifikantní nádor pouze u 40.43% pacientů s klinicky signifikantním nádorem zjištěným z definitivního preparátu po radikální prostatektomii. Tyto nálezy mohou upozornit na reálnou šanci podhodnocení klinicky signifikantního nádoru